November 13, 2026 · Blood · DOI: 10.1182/blood.2026033948

CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.

Listen to this summary

Myeloproliferative neoplasms driven by mutant calreticulin (CALRmut) are currently curable only with allogeneic stem cell transplantation, which also destroys healthy stem cells. This study asks whether CALRmut is consistently displayed on the surface of MPN stem cells so they can be targeted selectively. The authors developed a high-affinity CALRmut-specific CAR-T cell therapy (hAB2) that, in patient-derived xenograft models, eliminated MPN-propagating stem cells while sparing normal human and host blood cell production, supporting transplant-free immunotherapy with curative potential.

Daniel C Choi, Giovanni Medico, Irina V Lebedeva, Elisabeth K Nyakatura, Clarisse Kayembe, Franco Castillo Tokumori, Pouneh Kermani, Nassima Messali, Olivia Vergnolle, Abigail Taylor, Alexandra M Satty, Arvin Eric Borja Ruiz, Maria Mia Yabut, Urko Del Castillo, Paul Balderes, Manuel Baca, Giorgio Ga Inghirami, Joseph Michael Scandura

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play